Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
US commission recommends federal research revamp to avoid losing global biotech edge
(16h)
FTC outlines antitrust case against Edwards' $945M JenaValve acquisition
(17h)
AbbVie launches lab space award program for Quebec biotechs
(19h)
GE HealthCare presents photon-counting CT system for FDA review
(20h)
Lawmakers probe FDA’s new priority voucher program, cite corruption and rushed review concerns
(21h)
Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes
(23h)
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
(1d)
J&J MedTech bolsters stroke R&D programs in Ireland
(1d)
Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program
(1d)
Abbott to replace certain FreeStyle Libre 3 CGMs after incorrect readings and death reports
(1d)
BioPharma Dive
Novartis wins approval to use SMA gene therapy in older patients
(20h)
Gilead scoops up a preclinical cancer program
(21h)
How do Big Pharma employees rate their CEOs?
(21h)
Kelun, Merck tout ADC as potential first-line treatment in lung cancer
(21h)
Bayer’s experimental blood-thinner notches trial win in stroke prevention
(1d)
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s trials
(1d)
FDA probes effects of Takeda rare disease drug after patient death
(1d)
Biogen strikes deal with Versant-backed biotech to expand immune portfolio
(1d)
APOE4 and CRISPR are reframing Alzheimer’s Risk
(2d)
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
(4d)
Endpoints News
Sanofi headquarters raided in broader French tax fraud investigation
(36m)
Kallyope scraps one of two mid-stage migraine drugs
(1h)
Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN
(11h)
CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks
(13h)
What a team of ex-Amazon employees are building next in healthcare
(18h)
Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices looms
(18h)
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
(20h)
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
(21h)
Novartis plans to lay off 550 workers at Swiss factory
(22h)
FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophy
(1d)
BioSpace
Are Animals Out? How NAMs Are Changing the Rules of the Game
(5h)
Budget Cuts Are Hobbling American Innovation
(6h)
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
(20h)
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal
(20h)
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
(22h)
Lilly Redefines the Pharma Mega-Blockbuster
(22h)
Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could "Shift Paradigm" in Myeloma
(22h)
Pazdur Questions Legality, Safety of FDA’s Expedited Drug Approvals Programs
(22h)
Former DARPA Official Jackson Named ARPA-H Head
(23h)
As CGT Struggles To Scale, FDA's New Designation Could Smooth Post-Approval Pivots
(1d)
STAT News
Proposal to remove advanced nursing from list of ‘professional’ degrees is short-sighted and dangerous
(2h)
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
(2h)
Why beagles are the No. 1 dog for medical research
(2h)
Why my colleagues and I are undertaking an independent review of the hepatitis B birth dose
(2h)
Trump administration quietly unveils new round of Medicare-negotiated drug prices
(12h)
FDA approves Otsuka kidney disease therapy
(14h)
Major health insurers like Humana, UnitedHealth are cutting broker commissions to avoid costly Medicare enrollees
(14h)
Therapy chatbot study lands with a thud
(18h)
We’re reading about a Novo next-gen diabetes drug, a Novartis gene therapy, and more
(22h)
The hidden reason lung cancer screening is not working
(1d)
BioPharma Trend
Ginkgo Bioworks Launches Open-Source Pharmacology Framework for AI Drug Discovery
(6d)
Antheia and TAPI Announce Strategic Partnership to Scale Biosynthetic Pharmaceutical Manufacturing
(6d)
Terray Launches Experiment-Driven Machine Learning Platform for Small-Molecule Discovery
(1w)
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(2w)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(3w)
Companies Making Automated Drug Discovery a Reality
(3w)
Five Companies Leading the Way in 3D Bioprinting
(3w)
Roche and Manifold Bio's $55M-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases
(3w)
Flatiron Health Launches Six AI Blood Cancer Datasets Covering 505,000 Patients
(4w)
Recursion Unveils Whole-Genome Microglia Map With Roche and Genentech
(4w)
Drug Channels
The Hidden Burdens of Cancer Care: When Insurers Override Doctors
(6d)
Drug Channels News Roundup, November 2025: PBM Revolution, Cuban’s Stelara Challenge, Express Scripts’ Price Games, U.S. Drug Spending Reality, and the AFP Reckoning
(1w)
The $700 Copay That Changed Everything
(2w)
Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses
(2w)
Drug Channels Outlook 2026: Live Webinar with Adam J. Fein, Ph.D., on PBMs, Part D, DTC Strategies, Drug Policy Trends, and More
(2w)
Hubs, AI, and the New Era of Revenue Protection in Patient Access
(3w)
As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact
(4w)
Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble
(4w)
Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting
(4w)
Let’s Be DIRECT: We Have an Access and Affordability Problem to Solve
(1mo)
European Biotechnology Magazine
Novo Nordisk’s semaglutide fails in Alzheimer’s
(2h)
Gilead acquires Sprint Bioscience TREX1 programme
(1d)
AGC Biologics to manufacture dual AAV therapies for AAVantgarde
(4d)
Melatonin: a promising new approach in Alzheimer’s treatment
(4d)
Giredestrant demonstrates efficacy in early-stage breast cancer
(1w)
Avanzanite secures €32m Series A funding
(1w)
Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom
(1w)
MitoRx Therapeutics advances next-generation obesity therapy
(1w)
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
(1w)
Medicxi announces new €500m biotech investment fund
(1w)
Drug Hunter
paltusotine
(18h)
October 2025 Patent Highlights
(4d)
October 2025
(5d)
elinzanetant (NT-814)
(6d)
TCIPs: Heterobifunctional Compounds for Gene Activation
(6d)
daraxonrasib (RMC-6236)
(1w)
Patent Target Brief: Macrocycles Targeting the LAG3:MHC-II Protein–Protein Interactions
(1w)
taletrectinib
(2w)
Will a New Binding Approach Reinvigorate Caspase-1 as a Therapeutic Target for Autoimmune Disorders?
(2w)
nerandomilast (BI 1015550)
(2w)
Labiotech.EU
11 neuroscience biotech companies you should know about
(22h)
Six key obesity deals in 2025
(5d)
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
(5d)
Eight CAR-T cell therapy companies you should know about
(7d)
Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates
(1w)
On the fast track to the clinic: early decisions in drug development
(1w)
Precision psychiatry is the future of mental healthcare
(1w)
10 gene therapy companies you should know about
(2w)
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
(2w)
iGEM Jamboree: leap into the synthetic biology future
(2w)
Bio IT World
Follow the Money: Enveloped Delivery Vehicle Technology, Oral Medication for Inflammatory, Neurological Diseases, More
(1d)
Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina
(2d)
Ginkgo Datapoints Launches Virtual Cell Pharmacology Initiative
(5d)
The Women’s Health Gap: 5 Cautionary Tales of Clinical Blunders
(1w)
ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas
(1w)
Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?
(2w)
Why Overlooking Female Biology Still Impairs Drug Development
(2w)
United Genetic, Epigenetic Readouts From The Same DNA Molecule
(2w)
Revolutionizing ADC Manufacturing: How Single-Use Technologies Are Reshaping Biopharma Efficiency and Safety
(3w)
DNA Nanotech Brings Precision Drug Monitoring to At-Home Use
(3w)
GEN News
Mapping the Neural Mechanism Behind Social Isolation Following Immune Challenge
(11h)
Backbone Potential: Actuate’s Elraglusib Shows Promise vs. Pancreatic Cancer
(12h)
Industry-Academia Collaboration Formed to Improve Cell and Gene Therapy Manufacturing
(12h)
Cyanobacterial Pigments Advance Biomedicine Through Smarter Bioprocessing
(19h)
Microbiome Analysis Sees Cleanroom Contaminants Other Methods Miss
(19h)
New Standards Aim to Support Gene Therapy Manufacturers
(19h)
Precipitation Offers Low-Cost Solution for Monoclonal Manufacturing
(19h)
Proteome-Wide AI Model Supports Rare Disease Diagnosis Using Evolution
(20h)
AstraZeneca Plans $2 Billion Biomanufacturing Investment in Maryland
(23h)
Metformin’s Surprising Potential Benefits in Type 1 Diabetes Therapy
(1d)
Cure Today
Understanding Stage 1 Polycythemia Vera: What Every Patient Should Know
(14h)
How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer
(15h)
FDA Approves Imfinzi Plus Chemo in GC/GEJC
(16h)
More Than a Cyst: The Fear Cancer Leaves Behind
(18h)
Basics of Squamous Cell Bladder Cancer
(19h)
AVZO-103 Wins FDA Designation for Previously Treated Urothelial Cancer
(20h)
Expert Explains Recent Advances in Early Stage Lung Cancer Surgery
(22h)
How I Navigate Grief and the Holidays After Cancer Loss
(1d)
How New Therapies Are Changing the Game for Small Cell Lung Cancer
(1d)
SANRECO Trial Explores Divesiran for Polycythemia Vera Treatment
(1d)
Contract Pharma
Sanofi and Regeneron’s Dupixent Approved in EU
(20h)
BioMed X, AbbVie Launch New Research Project Focused on Anhedonia
(22h)
The Future of Oral Solids
(1d)
Roche Adopts Veeva Vault CRM
(2d)
AstraZeneca to Invest $2B in Maryland
(2d)
Derisking Global Supply Chain Networks with Foreign Trade Zones
(4d)
AGC Biologics Enters Gene Therapy Manufacturing Agreement with AAVantgarde
(5d)
Novartis to Create New Flagship Manufacturing Hub in North Carolina
(5d)
Overcoming Solubility Challenges at Hovione’s Expanded NJ Site
(5d)
ProFound Therapeutics, Quotient Therapeutics Enter Collaborations with GSK
(6d)
Pharma Times
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
(23h)
FDA approves Keytruda and Keytruda Qlex with Padcev for bladder cancer
(1d)
Academy and Wellcome strengthen partnership with £27m agreement to boost UK health research
(2d)
Bayer’s asundexian shows promise in landmark phase 3 stroke study
(2d)
Gobivaz approved across Europe as first Simponi biosimilar
(6d)
Poolbeg granted European patent for POLB 001
(6d)
TARA-002 shows strong early results in trial for paediatric lymphatic malformations
(6d)
Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
(7d)
Cellbyte raises $2.75m to slash drug launch timelines with AI
(1w)
GSK and Imperial launch £45m AI-powered AMR research drive
(1w)
Medcity News
FamilyWell Health Lands $8M to Grow Women’s Mental Health Support
(12h)
Boise’s Leading Sedation Dentistry Practices: A Comprehensive Guide
(12h)
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?
(12h)
The Opportunity being Missed in UK Healthcare Buyouts
(21h)
Orthopedics Cracked the Code on Wait Times: Here’s How They Did It
(21h)
MedCity Pivot Podcast: Could This Device Make Managing Brain Health Easier?
(1d)
Quality Isn’t Just a Checkbox — Can Better Workforce Skills Drive Lower Costs?
(1d)
Lawmakers Introduce Multiple Bills Aimed at Medicare Advantage Reform
(1d)
Precision vs. Power: How Nimble Innovators Are Expanding Possibilities in Surgical Robotics
(1d)
How Hospitals Can Blunt the Effects of Tariffs
(2d)
Chemical & Engineering News
Nov. 25 Business Watch: Flexsys readies safer tire additive; Moderna halts trials of 3 mRNA drugs
(15h)
These archaea built a distinct genetic code to put pyrrolysine in proteins
(16h)
Reactions: Plastics recycling
(18h)
COP30 final agreement omits fossil fuels
(18h)
What Hitler’s DNA and the dire wolf teach us about science
(19h)
Wild seal milk rivals human milk in sugar complexity
(19h)
Molecular tools may help us locate mass graves
(1d)
Molecule-maker Onepot.AI launches with $13 million
(1d)
Ultrasensitive sensor tracks flu- and COVID-19-fighting antibodies
(1d)
Comment: Staying safe during stressful times
(1d)
The Pharma Letter
Accelerated FDA approval for Otsuka’s Voyxact
(36m)
One thing the US Senate can agree on: It’s time to fix 340B
(1h)
TransCon CNP PDUFA delay likely a speed bump to approval
(1h)
AI in clinical trials: why industry must lead in shaping regulation
(18h)
Teva wins EC nod for Prolia and Xgeva biosimilars
(19h)
Otsuka files for US approval for centanafadine in ADHD
(19h)
Broader NICE recommendation for GSK’s Jemperli
(20h)
Regulatory round-up: 25 November 2025
(20h)
Zetagen raises $12.9M to transform breast cancer care
(20h)
GV20 advances ADC partnership with Mitsubishi Tanabe
(20h)
Targeted Oncology
FDA Approves Durvalumab Plus FLOT in Early Stage Gastric/GEJ Cancers
(17h)
FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer
(17h)
Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL
(18h)
NBM-BMX Earns FDA Orphan Drug Status for Uveal Melanoma
(19h)
Durvalumab/Chemoradiotherapy Fails to Meet Efficacy, Safety in PACIFIC-2 Trial
(20h)
STOMP Trial Analysis Reveals Immunomodulatory Effects of Selinexor in RRMM
(21h)
Dr Benjamin George: Cancer Care Is “Done as a Team”
(23h)
CBR Polling Shows Rapid Uptake of Darolutamide in mHSPC
(1d)
BMI in CAR T: Overweight Status Predicts Poorer Outcomes
(1d)
Understanding the Role of Mutations in Staging of Low-Risk MDS
(1d)
MedWatch
Demant took market share among US veterans in October
(3h)
Analyst impressed by Novo Nordisk's new amycretin data
(21h)
Novo Nordisk's amycretin shows weight loss of up to 14.5%
(22h)
Novo Nordisk follows competitor: New AI director to boost competitiveness
(22h)
Investors on Novo Nordisk's Alzheimer's flop: "It's fuel on the fire"
(1d)
Analyst: Novo Nordisk's core plan unaffected by disappointing Alzheimer's study
(1d)
Sanofi and Regeneron get EU approval for Dupixent as urticaria treatment
(1d)
Agilent Technologies disappoints with new earnings forecast
(1d)
Report: European biotech misses out on billions of euros
(2d)
Analyst on failed Novo study: “Really difficult to demonstrate success”
(2d)
In The Pipeline
Alzheimer's Clinical Trial Results, Sadly Running True to Form
(14h)
Alcohol And Fructose, Tangled (and Untangled?)
(1d)
Reverse Proteolysis, Will You Look At That
(4d)
Thinking About Running a Phenotypic Assay?
(1w)
LLMs for Medical Practice: Look Out
(1w)
Huge Channels or No Channels: You Pick
(2w)
Biochemical Tungsten - Really
(2w)
Reaction Stirring, Part Two
(2w)
TrkB, BDNF, and Depression
(2w)
Making Pills. But Not Making Them Here.
(3w)
Pharmaphorum
Otsuka joins IgAN market with Voyxact approval in US
(49m)
Latest Medicare pricing cuts promise $12bn in savings
(1h)
Data sets up phase 3 trials for Novo's amycretin in diabetes
(22h)
NICE backs NHS use of Autolus' leukaemia CAR-T
(23h)
£800m life sciences cluster opens in London
(1d)
Innovent files high-dose mazdutide for obesity in China
(1d)
Novartis' SMA gene therapy cleared for wider use in US
(1d)
Angelini rapped for criticism of EMA approval
(2d)
Disappointment as Novo's oral GLP-1 fails in Alzheimer's
(2d)
Stroke data breathes life back into Bayer's asundexian
(2d)
Drug Discovery Weekly
10x Genomics launches international cancer research project
(20h)
Revolutionary therapy treats Hunter syndrome for first time
(20h)
DDW Highlights: 25 November 2025
(23h)
RNA-based gene therapy offers new hope for ALS treatment
(1d)
Study reveals how water influences cancer drug potency
(1d)
eBook: What’s new in neuroscience drug discovery?
(1d)
Register your interest for DDW track at SLAS2026
(1d)
Semaglutide shows no benefit in Alzheimer’s disease
(1d)
What’s new in neuroscience drug discovery?
(1d)
First patient dosed in trial of MTHFD1/2 inhibitor
(2d)
HIT Consultant
RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform
(6h)
Fay and Withings Partner to Connect Health Data with Personalized Nutrition Counseling
(6h)
How Optimized Print Infrastructure Closes Compliance Gaps in Healthcare
(6h)
Why Empathy, Not Just More Features, is the Fix for Patient Portals
(10h)
Greece and Sword Health to Build AI-Powered Healthcare Front Door
(22h)
Elation Health AI Saves Primary Care Clinicians Over Two Hours Daily, Reducing Burnout
(22h)
Barco and Avatar Medical Launches Glasses-Free 3D Display for Clinical Consultations
(1d)
AI Health Care Accreditation: Benefits, Considerations and Industry Leaders
(1d)
Joi + Blokes Launches “Beyond the Labs” Telehealth Program for Personalized, High-Touch Consultations
(1d)
Why Compromised OT Devices are the Biggest Cyber Risk for Hospitals
(1d)
Insights: Pink Sheet
Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge
(2h)
US FDA Approves First Reformulated Rx Ranitidine, Five Years After Withdrawal
(9h)
As US FDA Turns: Can Makary, Prasad And Pazdur Make It Work?
(12h)
Obscure User Fee Provision Gives Generic Drug Sponsors More Time To Pay Fees Post-Shutdown
(12h)
EU HTA Regulation: PICO Consolidation Going Well, Analysis Feasibility A Challenge
(19h)
UK Off-Patent Industry Urges Focus On Five Priorities Ahead Of Govt Budget
(23h)
England Becomes First In Europe To Reimburse Autolus’ CAR-T Aucatzyl
(1d)
Achieving More With Less: US FDA Offers ‘Road Map’ For AI In Rare Diseases
(1d)
CBER Poised for Research Shakeup As Prasad Makes Unproven Claims About ‘Polluted Science’
(1d)
GDUFA IV: US FDA Wants to ‘Streamline’ Formal Meeting Structure
(1d)
BioXconomy
J&J acquires Halda for $3.05bn to advance cancer treatment platform
(33m)
Curavit partners with Cenmed to enhance decentralized clinical trial logistics
(17h)
9amHealth launches ‘No-Barriers Bundle’ to expand employer access to obesity meds, virtual care
(17h)
9amHealth launches ‘No-Barriers Bundle’ to expand employer access to obesity meds, virtual care
(17h)
The silver lining in Europe's biopharma storm
(20h)
CRScube buys Mednet to expand North American market presence
(20h)
ASOs could delay blindness in children with ultra-rare genetic disease
(20h)
Ampersand merges P95 and Julius Clinical to form global CRO
(1d)
Eyes on Asia: Sanegene Bio, ABL Bio, Third Arc Bio
(2d)
GLP-1 killer? Oligo therapy hits obesity at its source
(4d)
BioCentury
Phase III comeback for Bayer’s asundexian in stroke prevention: Clinical Report
(11h)
Novartis hoping to lift SMA gene therapy sales with Itvisma approval
(12h)
Semaglutide’s Alzheimer’s miss: A case study in balancing ambition and evidence
(16h)
FDA’s moving goalposts & China’s innovation arc — a BioCentury podcast
(1d)
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report
(1d)
FDA staffing exodus degrading oversight
(1d)
DARPA vet Fisher to lead U.K. R&D funding agency ARIA
(4d)
Cautious optimism and M&A momentum — A BioCentury podcast
(4d)
Four companies raise nearly $950M in follow-ons: Public Equity Report
(4d)
Iambic: Turning AI and automation into a two-year chemistry-to-clinic cycle
(4d)